This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
When "no data" is the complete and final answer: if there is no published human data on a compound, that is the state of knowledge. Hope is not a substitute and reasoning from theory is not a substitute. That is not a reason for shame; it is the honest epistemic position.
Where I part company with post #61, and it is a narrow parting.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Not a strong opinion, just a consistent one.
Post #61 is the version of this I will quote in future. One addition.
Storage guidance for the less common material is usually copied from the incretin guidance and may not apply. Where the supplier has its own stability statement, that is the one to use.
If anyone has run this properly I would rather read that than my own guess.
Building on post #65 rather than restating it.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Noting that the question and the thing people usually mean by it are different.
Everything in post #65 holds. The case it does not cover is the one I have.
How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.
Two people can read the same figure differently here and both be reasonable.
Narrowing post #68, because the general version has more than one answer.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
One of those cases where knowing the mechanism does not help the decision.
Sensible. I would want the same detail before I acted on it either.
Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation and erections of sustained duration, the second of which is specific enough that it is the first thing worth mentioning.
Confirming post #72 from a second method, which matters more than confirming it from a second person.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
The evidence for this is thinner than the way I have phrased it suggests.
I had written a reply contradicting post #70 and deleted it. Here is what survived.
When "no data" is the complete and final answer: if there is no published human data on a compound, that is the state of knowledge. Hope is not a substitute and reasoning from theory is not a substitute. That is not a reason for shame; it is the honest epistemic position.
The strength of my opinion here exceeds the strength of my evidence.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Worth one more sentence than it usually gets.
Answering the question post #74 raises rather than the one it answers.
The tanning compounds carry a specific practical point that is not pharmacological: any change to a pigmented lesion is a reason to see a clinician, and that is not a matter of opinion or of dose.
The interesting part of this is the exception, and I do not understand the exception.
Post #76 is the version of this I will quote in future. One addition.
The honest summary for most of this subcategory: a plausible mechanism, animal data, and first-hand accounts. Saying so is more useful than assembling the accounts into something that reads like evidence.
Written from notes rather than memory, which is why the numbers are specific.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
A modest claim, modestly supported.
Narrowing post #76, because the general version has more than one answer.
Anyone submitting an unusual compound for testing should tell the laboratory what it is rather than what it is sold as. Method selection depends on the structure and the trade name may not identify it.
I have kept the units in throughout, for the obvious reason.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
That is a description of practice, not a recommendation of it.
Noted, and I have changed what I was going to do on the strength of it.
Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption or treatment. The label does not tell you whether the molecule is safe, efficacious, or what its effects are.
Marking that as an opinion rather than a finding.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
When "no data" is the complete and final answer
Asking directly, because I could not find a straight answer: When "no data" is the complete and final answer Asking about the compound itself rather than about a trial of it. I have read the maintained page…
|
+154 | 165 | 6.3k | 15mo |
|
Research-use-only status: what it means legally and practically — a second dataset
Research-use-only status: what it means legally and practically — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Research-use-only status. It…
|
+109 | 125 | 2k | 16mo |
|
Coming back to: Reading a supplier's product description as a marketing document
Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. Documentation question rather than a pharmacological one,…
|
+35 | 39 | 688 | 5mo |
|
How to research a compound with no human data without deceiving yourself
Asking directly, because I could not find a straight answer: How to research a compound with no human data without deceiving yourself Question about what the published evidence for this compound actually…
|
+107 | 119 | 11k | 12mo |
|
Compounds this community declines to help with, and why
Compounds this community declines to help with, and why — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a compound without…
|
+81 | 87 | 35k | 10mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Pharmaceutical compounding rules, summarised from primary sources
Pharmaceutical compounding rules, summarised from primary sources — setting out what I have, and where I think it stops being reliable. Asking what a regulator's document actually says, since the summaries of…
|
+135 | 163 | 46k | 17mo |
|
Coming back to: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Writing it up because I had to work it out twice and would rather nobody else did. GHRH analogues versus ghrelin mimetics — I…
|
+9 | 13 | 249 | 17mo |
|
Second pass at: How to research a compound with no human data without deceiving yourself
Second pass at: How to research a compound with no human data without deceiving yourself Writing it up because I had to work it out twice and would rather nobody else did. The question about research a…
|
+64 | 71 | 2.5k | 13mo |
|
Revisiting: Oral versus injected administration claims for BPC-157
On the subject in the title: Revisiting: Oral versus injected administration claims for BPC-157 Working notes rather than a conclusion. A follow-up question about Oral versus injected administration claims…
|
+23 | 27 | 7.7k | 15mo |
|
Second pass at: Why this subcategory is stricter about sourcing than most
Second pass at: Why this subcategory is stricter about sourcing than most — setting out what I have, and where I think it stops being reliable. A comparison question rather than a question about one compound.…
|
+120 | 129 | 61k | 11mo |